The company’s net income for FY23 was $3.76bn. Credit: JHVEPhoto / Shutterstock.com.

Medtronic has reported a revenue of $31.23bn in fiscal year 2023 (FY23), down by 1.4% from $31.69bn in FY22.

The cardiovascular divisions posted a 1.3% rise in revenue to $11.57bn in FY23, compared to $11.42bn in the prior year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The medical surgical divisions witnessed a 7.7% drop in revenue to $8.43bn during the year from $9.14bn in FY22.

Medtronic reported a 2% year-over-year revenue growth for its neuroscience business in FY23 to $8.96bn, while the revenue of its diabetes divisions fell by 3.3% from $2.33bn to $2.26bn.

During the fiscal year, the company’s net income declined by 25.2% year-over-year to $3.76bn.

The diluted earnings per share was $2.82, down by 24% from $3.73 in FY22.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The cash flow from operations for FY23 amounted to $6.039bn, marking an 18% decrease year-over-year, while the free cash flow during the same period fell by 23% year-over-year to $4.58bn.

Medtronic chairman and CEO Geoff Martha said: “We had a strong finish to our fiscal year, with our fourth quarter top and bottom-line results coming in ahead of expectations.

“Our accelerating revenue growth was broad-based, driven by procedure volume recovery, supply improvements and innovative product introductions.”

In the fourth quarter (Q4) of FY23, the company recorded a revenue of $8.54bn, reflecting a 5.6% increase compared to the same period a year ago.

Its Q4 organic revenue was driven by solid performances in its medical surgical, neuroscience and cardiovascular portfolios, as well as in diabetes markets outside the US.

During the quarter, the net income fell by 21% to $1.18bn, against $1.49bn in Q4 of FY22.

In its financial outlook for FY24, Medtronic projects its organic revenue growth to be between 4% and 4.5%.